RecruitingPhase 1NCT07404137
A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food
A Randomized, Single Dose, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of Single Dose, Orally Administered, Combined Zibotentan/Dapagliflozin in Healthy Participants
Sponsor
AstraZeneca
Enrollment
26 participants
Start Date
Feb 16, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to investigate the concentrations of zibotentan and dapagliflozin in blood when given with and without food in healthy participants.
Eligibility
Min Age: 18 YearsMax Age: 60 Years
Inclusion Criteria2
- Healthy male and/or female of non-childbearing potential. Participants with suitable veins for cannulation or repeated venipuncture.
- Have a body mass index (BMI) between 18 and 32 kg/m2 inclusive and weigh at least 50 kg and no more than 100 kg (inclusive) at Screening.
Exclusion Criteria8
- History of any clinically important disease or disorder.
- History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.
- Any clinically important illness, medical/surgical procedure, or trauma.
- Any clinically important abnormalities in clinical chemistry, hematology, or urinalysis results or other laboratory values or vital signs.
- Any positive result on screening for serum Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), Hepatitis C virus (HCV) antibody, or Human immunodeficiency virus (HIV) (Type 1 and 2) antibodies.
- Known or suspected history of alcohol or drug abuse or excessive intake of alcohol.
- History or ongoing allergy/hypersensitivity, to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i- eg, dapagliflozin, empagliflozin), or zibotentan or other Endothelin Receptor Antagonist (ERAs- eg, ambrisentan, atrasentan,bosentan), or any of the excipients in the zibotentan/dapagliflozin tablets.
- Participants who have previously received zibotentan.
Interventions
DRUGZibotentan/Dapagliflozin FDC
Zibotentan/Dapagliflozin FDC will be administered as an oral tablet.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07404137
Related Trials
A Study to Investigate the Pharmacokinetics of Different Formulations and Safety of AZD5004 in Healthy Participants Aged 18 to 55 Years
NCT074558252 locations
Cognitive Strategies in Early Psychosis 1
NCT072314971 location
Evaluation of See.d as an Automated Blood Sample Preparator for Multiple Liquid Biopsy Applications
NCT060971561 location
A Phase 1 Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)
NCT073613541 location
OCTA in Cardiovascular Disease and Healthy Controls
NCT073596641 location